共 35 条
[1]
Johnston D(1992)Drug-patient interactions and their relevance in the treatment of heart failure Am J Cardiol 70 109C-112C
[2]
Duffin D.(1991)Pharmacokinetic profile and tolerability of pimobendan in patients with terminal renal insufficiency Eur J Clin Pharmacol 40 107-111
[3]
Przechera M(1991)Phase I study of a heart failure drug, pimobendan capsules (UD-CG 115BS): Single oral doses of 1.25 mg, 2.5 mg, 5.0 mg, and 7.5 mg Rinsyo to Kenkyu 68 2154-2172
[4]
Roth W(1988)Pimobendan (UD-CG 115BS) in the treatment of severe congestive heart failure: An acute haemodynamic Br J Clin Pharmacol 25 323-329
[5]
Kühlkamp V(1989) cross-over and double-blind study with two different doses J Cardiovasc Pharmacol 14 302-310
[6]
Risler T(1988)Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing Chest 93 1159-1164
[7]
Haehl M.(1995)Pimobendan (UD-CG 115BS) in chronic congestive heart failure: Short term and one-month effects of a new inotropic vasodilating agent Clin Pharmacol Ther 57 610-621
[8]
Shigematsu A(2001)Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing Clin Pysiol 21 661-672
[9]
Kondo U(1991)Heart failure and neuroendocrine activation: Diagnostic, prognostic and therapeutic perspectives J Clin Invest 87 1402-1412
[10]
Aoyama K(1993)Brain natriuretic peptide (BNP) as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, ANP and BNP Circulation 88 1004-1009